Milestone Pharmaceuticals Inc. (MIST) vs Neuraxis, Inc. (NRXS)

Milestone Pharmaceuticals Inc. and Neuraxis, Inc. are both Biotechnology companies. Milestone Pharmaceuticals Inc. and Neuraxis, Inc. are of similar size ($99.0M and $97.3M). Neuraxis, Inc. has the higher net margin (−159.0% vs −1,586.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Neuraxis, Inc. leads on 11 and Milestone Pharmaceuticals Inc. on 4.

Valuation

Metric MIST NRXS Biotechnology median
P/E n/m n/m 7.88
P/S 20.68 17.24 11.47
P/B 6.01 13.61 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.02 n/m 0.74
EV/Sales (0.35) 15.68 10.73
Earnings yield (87.34%) (10.32%) (28.84%)
Free cash flow yield (56.26%) (6.31%) (23.03%)

Profitability

Metric MIST NRXS Biotechnology median
Gross margin 13.27% 85.56% 65.16%
Operating margin (1,479.69%) (144.51%) 0.00%
Net margin (1,586.01%) (159.01%) 0.00%
Free cash flow margin (1,163.79%) (106.10%) 0.00%
Return on equity (35,522.62%) (153.96%) (57.72%)
Return on assets (73.36%) (98.96%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MIST NRXS Biotechnology median
Revenue growth (TTM) — 65.22% 5.64%
EPS growth (last fiscal year) (11.94%) 22.13% —
Revenue growth, 5-year CAGR — 13.08% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MIST NRXS Biotechnology median
Debt to equity 3.25 0.00 0.00
Current ratio 8.13 3.04 4.73
Net debt to EBITDA 0.79 0.64 0.96

Dividend

Metric MIST NRXS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric MIST NRXS Biotechnology median
Market cap 98.96m 97.32m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack